Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in a growing number of malignancies. However, overcoming primary or secondary resistances is difficult due to pharmacokinetics issues and side effects associated with high systemic exposure. Local or regional expression of monoclonal antibodies (mAbs) using gene therapy vectors can alleviate this problem. In this work, we describe a high-capacity adenoviral vector (HCA-EFZP-aPDL1) equipped with a mifepristone-inducible system for the controlled expression of an anti-programmed death ligand 1 (PD-L1) blocking antibody. The vector was tested in an immune-competent mouse model of colorectal cancer based on implantation of MC38 cells. A single local administration of HCA-EFZP-aPDL1 in subcutaneous lesions led to a significant reduction in tumor growth with minimal release of the antibody in the circulation. When the vector was tested in a more stringent setting (rapidly progressing peritoneal carcinomatosis), the antitumor effect was marginal even in combination with other immune-stimulatory agents such as polyinosinic-polycytidylic acid (pI:C), blocking mAbs for T cell immunoglobulin, mucin-domain containing-3 (TIM-3) or agonistic mAbs for 4-1BB (CD137). In contrast, macrophage depletion by clodronate liposomes enhanced the efficacy of HCA-EFZP-aPDL1. These results highlight the importance of addressing macrophage-associated immunoregulatory mechanisms to overcome resistance to ICIs in the context of colorectal cancer.     

Lipid Droplet Motility Increases Following Viral Immune Stimulation

Lipid droplets (LDs) have traditionally been thought of as solely lipid storage compartments for cells; however, in the last decade, they have emerged as critical organelles in health and disease. LDs are highly dynamic within cells, and their movement is critical in organelle–organelle interactions. Their dynamics are known to change during cellular stress or nutrient deprivation; however, their movement during pathogen infections, especially at very early timepoints, is under-researched. This study aimed to track LD dynamics in vitro, in an astrocytic model of infection. Cells were either stimulated with a dsRNA viral mimic, poly I:C, or infected with the RNA virus, Zika virus. Individual LDs within infected cells were analysed to determine displacement and speed, and average LD characteristics for multiple individual cells calculated. Both LD displacement and mean speed were significantly enhanced in stimulated cells over a time course of infection with an increase seen as early as 2 h post-infection. With the emerging role for LDs during innate host responses, understanding their dynamics is critical to elucidate how these organelles influence the outcome of viral infection.     

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC patients. In recent years, however, immunotherapy has re-emerged as a promising therapeutic option to stimulate antitumor immunity, particularly with the use of immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. There is increasing evidence that ICIs may be especially beneficial in specific subgroups of patients with high PD-L1 tumor expression, high tumor mutational burden, or tumors with high microsatellite instability/mismatch repair deficiency. If we are to improve the efficacy of ICIs, it is crucial to have a better understanding of the mechanisms of resistance to ICIs and to identify predictive biomarkers to determine which patients are most likely to benefit. This review focuses on the current status of ICIs for the treatment of mCRPC (either as monotherapy or in combination with other drugs), mechanisms of resistance, potential predictive biomarkers, and future challenges in the management of mCRPC.     

In Vitro Characterization of Human CD24hiCD38hi Regulatory B Cells Shows CD9 Is Not a Stable Breg Cell Marker

Regulatory B (Breg) cells are endowed with immune suppressive functions. Various human and murine Breg subtypes have been reported. While interleukin (IL)-10 intracellular staining remains the most reliable way to identify Breg cells, this technique hinders further essential functional studies. Recent findings suggest that CD9 is an effective surface marker of murine IL-10 competent Breg cells. However, the stability of CD9 and its relevance as a unique marker for human Breg cells, which have been widely characterized as CD24^hiCD38^hi, have not been investigated. Here, we demonstrate that CD9 expression is sensitive to in vitro B cell stimulations. CD9 expression could either be re-expressed or downregulated in purified CD9-negative B cells and CD9-positive B cells, respectively. We found no significant differences in the Breg differentiation capacity of the CD9-negative and CD9-positive B cells. Furthermore, CD9-positive B cells co-express CD40 and CD86, suggesting their nature as B cell activation or co-stimulatory molecules, rather than regulatory ones. Therefore, we report the relatively unstable CD9 as a distinct surface molecule, indicating the need for further research for a more reliable marker to purify human Breg cells.     

In Vivo Analysis of the Biocompatibility and Bone Healing Capacity of a Novel Bone Grafting Material Combined with Hyaluronic Acid

The present in vivo study analyses both the inflammatory tissue reactions and the bone healing capacity of a newly developed bone substitute material (BSM) based on xenogeneic bone substitute granules combined with hyaluronate (HY) as a water-binding molecule. The results of the hyaluronate containing bone substitute material (BSM) were compared to a control xenogeneic BSM of the same chemical composition and a sham operation group up to 16 weeks post implantationem. A major focus of the study was to analyze the residual hyaluronate and its effects on the material-dependent healing behavior and the inflammatory tissue responses. The study included 63 male Wistar rats using the calvaria implantation model for 2, 8, and 16 weeks post implantationem. Established and Good Laboratory Practice (GLP)-conforming histological, histopathological, and histomorphometrical analysis methods were conducted. The results showed that the new hyaluronate containing BSM was gradually integrated within newly formed bone up to the end of the study that ended in a condition of complete bone defect healing. Thereby, no differences to the healing capacity of the control BSM were found. However, the bone formation in both groups was continuously significantly higher compared to the sham operation group. Additionally, no differences in the (inflammatory) tissue response that was analyzed via qualitative and (semi-) quantitative methods were found. Interestingly, no differences were found between the numbers of pro- and anti-inflammatory macrophages between the three study groups over the entire course of the study. No signs of the HY as a water-binding part of the BSM were histologically detectable at any of the study time points, altogether the results of the present study show that HY allows for an optimal material-associated bone tissue healing comparable to the control xenogeneic BSM. The added HY seems to be degraded within a very short time period of less than 2 weeks so that the remaining BSM granules allow for a gradual osteoconductive bone regeneration. Additionally, no differences between the inflammatory tissue reactions in both material groups and the sham operation group were found. Thus, the new hyaluronate containing xenogeneic BSM and also the control BSM have been shown to be fully biocompatible without any differences regarding bone regeneration.     

多表位DNA壳聚糖微球疫苗的体液免疫应答

目的研究多表位DNA壳聚糖微球疫苗的体液免疫应答。方法制备多表位DNA壳聚糖微球疫苗pcD-NA3.1-HME-3C3d,经鼻腔免疫小鼠,蛋白检测微孔试剂盒检测小鼠特异性IgG抗体水平。结果经免疫的小鼠均能产生针对各表位的特异性IgG抗体,DNA壳聚糖微球疫苗的抗体水平明显高于DNA疫苗。结论壳聚糖微球疫苗投递系统可提高多表位DNA疫苗的免疫应答效果。     

动态格点搜索的改进算法用于团簇结构快速优化

结合高效的动态格点搜索(DLS)算法与扰动操作(Perturbation Operation)提出一种新的改进方法(DLS-PO),用于确定团簇的最低能量结构。针对一个特定构型,DLS算法总能给出其对应搜索空间的最规则结构。然而,一次失败的DLS优化将消耗大量的运算资源。为此,采取原子移动和结构旋转的扰动操作成功地改变了构型,再结合后续的DLS操作,提高了优化效率。将该算法用于原子数高达309的Lennard-Jones团簇及100原子NP-B函数铝团簇的结构优化。优化结果显示相比于DLS算法,DLS-PO算法更为高效。     

An immune orthogonal learning particle swarm optimisation algorithm for routing recovery of wireless sensor networks with mobile sink

The growth of mobile handheld devices promotes sink mobility in an increasing number of wireless sensor networks (WSNs) applications. The movement of the sink may lead to the breakage of existing routes of WSNs, thus the routing recovery problem is a critical challenge. In order to maintain the available route from each source node to the sink, we propose an immune orthogonal learning particle swarm optimisation algorithm (IOLPSOA) to provide fast routing recovery from path failure due to the sink movement, and construct the efficient alternative path to repair the route. Due to its efficient bio-heuristic routing recovery mechanism in the algorithm, the orthogonal learning strategy can guide particles to fly on better directions by constructing a much promising and efficient exemplar, and the immune mechanism can maintain the diversity of the particles. We discuss the implementation of the IOLPSOA-based routing protocol and present the performance evaluation through several simulation experiments. The results demonstrate that the IOLPSOA-based protocol outperforms the other three protocols, which can efficiently repair the routing topology changed by the sink movement, reduce the communication overhead and prolong the lifetime of WSNs with mobile sink.     

两种方法提取琉璃苣叶多糖的理化性质 及生理活性

本研究旨在制备两种琉璃苣叶水溶性多糖，进一步探究其结构特征，并评价其降血糖、抗癌和免疫活性。采用纤维素酶辅助提取（BLP-1）和微波辅助提取法（BLP-2）制备琉璃苣叶水溶性多糖，并比较了BLP-1和BLP-2的理化性质，通过分析α-葡萄糖苷酶和α-淀粉酶的抑制效果来评价BLP-1和BLP-2的降血糖活性，通过检测HepG2、MX-1和A549细胞的抑制率来评价抗癌活性，通过检测RAW246.7的免疫因子分泌来评价免疫活性。结果表明，BLP-1和BLP-2具有不同的多糖和蛋白质含量。BLP-1和BLP-2由阿拉伯糖（Ara）、半乳糖（Gal）、葡萄糖（Glc）、木糖（Xyl）组成，但摩尔比组成不同，其分子量分别为20.1和22.6KDa。热重分析（TGA）表明BLP-2比BLP-1具有更稳定的结构。这两种多糖具有抑制α-葡萄糖苷酶和α-淀粉酶活性、抑制HepG-2、A549和MX-1癌细胞增殖以及激活巨噬细胞RAW 264.7细胞分泌免疫细胞因子以介导细胞免疫反应的潜力。两种多糖可作为新功能食品和医药产品中的生物活性成分，为进一步研究两种多糖的构效关系提供了理论依据。